BUZZ-Disc Medicine shares soar as rare disease drug performs excellently in key trial

October 19 - ** Disc Medicine (IRON.O) shares jumped 65.20% in pre-market trading to $93.90

** The company said its experimental drug Bitopertin (link) met all primary and secondary endpoints in a late-stage clinical trial for a rare disease

** Disc is testing Bitopertin for the treatment of erythropoietic protoporphyria, a blood disorder that makes patients extremely sensitive to sunlight

** The drug lowers levels of harmful substances associated with the disease, helping patients stay in sunlight longer without feeling pain

** Earlier this year, the U.S. Food and Drug Administration (FDA) rejected the approval (link) of Bitopertin, saying early studies failed to clearly link biomarker improvements with clinical benefit

** Disc plans to resubmit the U.S. approval application for the drug by the end of 2026 and expects the FDA to make a decision by mid-2027

** As of the close of trading on the previous day, the stock had fallen 28.4% so far this year

(For the convenience of non-English native speakers, Reuters has automated the translation of its reports into several other languages. Due to potential errors in automated translation or lack of required context, Reuters does not guarantee the accuracy of the automated translation text and provides it only for the convenience of readers. Reuters accepts no responsibility for any damages or losses caused by the use of the automated translation function.)